92 related articles for article (PubMed ID: 28394001)
1. Pharmacokinetics, biodistribution and antitumour effects of Sclerotium rolfsii lectin in mice.
Anupama S; Laha P; Sharma M; Pathak K; Bane S; Ingle AD; Gota V; Kalraiya RD; Yu LG; Rhodes JM; Swamy BM; Inamdar SR
Oncol Rep; 2017 May; 37(5):2803-2810. PubMed ID: 28394001
[TBL] [Abstract][Full Text] [Related]
2. The TF-antigen binding lectin from Sclerotium rolfsii inhibits growth of human colon cancer cells by inducing apoptosis in vitro and suppresses tumor growth in vivo.
Inamdar SR; Savanur MA; Eligar SM; Chachadi VB; Nagre NN; Chen C; Barclays M; Ingle A; Mahajan P; Borges A; Shastry P; Kalraiya RD; Swamy BM; Rhodes JM; Yu LG
Glycobiology; 2012 Sep; 22(9):1227-35. PubMed ID: 22653662
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of anticancer effect of Sclerotium rolfsii lectin in HT29 cells involves differential expression of genes associated with multiple signaling pathways: A microarray analysis.
Barkeer S; Guha N; Hothpet V; Saligrama Adavigowda D; Hegde P; Padmanaban A; Yu LG; Swamy BM; Inamdar SR
Glycobiology; 2015 Dec; 25(12):1375-91. PubMed ID: 26347523
[TBL] [Abstract][Full Text] [Related]
4. Sclerotium rolfsii lectin induces stronger inhibition of proliferation in human breast cancer cells than normal human mammary epithelial cells by induction of cell apoptosis.
Savanur MA; Eligar SM; Pujari R; Chen C; Mahajan P; Borges A; Shastry P; Ingle A; Kalraiya RD; Swamy BM; Rhodes JM; Yu LG; Inamdar SR
PLoS One; 2014; 9(11):e110107. PubMed ID: 25364905
[TBL] [Abstract][Full Text] [Related]
5. Exquisite binding specificity of Sclerotium rolfsii lectin toward TF-related O-linked mucin-type glycans.
Chachadi VB; Inamdar SR; Yu LG; Rhodes JM; Swamy BM
Glycoconj J; 2011 Jan; 28(1):49-56. PubMed ID: 21347715
[TBL] [Abstract][Full Text] [Related]
6. Efficacy studies of Sclerotium rolfsii lectin on breast cancer using NOD SCID mouse model.
Hegde P; Narasimhappagari J; Swamy BM; Inamdar SR
Chem Biol Drug Des; 2018 Aug; 92(2):1488-1496. PubMed ID: 29675931
[TBL] [Abstract][Full Text] [Related]
7. Sclerotium rolfsii lectin induces opposite effects on normal PBMCs and leukemic Molt-4 cells by recognising TF antigen and its variants as receptors.
Chachadi VB; Pujari R; Shastry P; Swamy BM; Inamdar SR
Glycoconj J; 2020 Apr; 37(2):251-261. PubMed ID: 31900725
[TBL] [Abstract][Full Text] [Related]
8. Sclerotium rolfsii lectin inhibits proliferation and induces apoptosis in human ovarian cancer cell line PA-1.
Eligar SM; Pujari R; Swamy BM; Shastry P; Inamdar SR
Cell Prolif; 2012 Oct; 45(5):397-403. PubMed ID: 22805123
[TBL] [Abstract][Full Text] [Related]
9. Molecular Cloning, Carbohydrate Specificity and the Crystal Structure of Two Sclerotium rolfsii Lectin Variants.
Peppa VI; Venkat H; Kantsadi AL; Inamdar SR; Bhat GG; Eligar S; Shivanand A; Chachadi VB; Satisha GJ; Swamy BM; Skamnaki VT; Zographos SE; Leonidas DD
Molecules; 2015 Jun; 20(6):10848-65. PubMed ID: 26076107
[TBL] [Abstract][Full Text] [Related]
10. Investigation of TF-binding lectins from dietary sources and SRL on proliferation and cell cycle progression in human colon HT29 and SW620 cells.
Belur S; Barkeer S; Swamy BM; Yu LG; Inamdar SR
Nutr Cancer; 2019; 71(4):634-642. PubMed ID: 30672325
[TBL] [Abstract][Full Text] [Related]
11. Sclerotium rolfsii lectin exerts insecticidal activity on Spodoptera litura larvae by binding to membrane proteins of midgut epithelial cells and triggering caspase-3-dependent apoptosis.
H V; Bhat GG; Inamdar SR; Gudihal RK; Swamy BM
Toxicon; 2014 Feb; 78():47-57. PubMed ID: 24291632
[TBL] [Abstract][Full Text] [Related]
12. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for the carbohydrate recognition of the Sclerotium rolfsii lectin.
Leonidas DD; Swamy BM; Hatzopoulos GN; Gonchigar SJ; Chachadi VB; Inamdar SR; Zographos SE; Oikonomakos NG
J Mol Biol; 2007 May; 368(4):1145-61. PubMed ID: 17391699
[TBL] [Abstract][Full Text] [Related]
14. Carbohydrate specificity of a lectin isolated from the fungus Sclerotium rolfsii.
Wu AM; Wu JH; Tsai MS; Hegde GV; Inamdar SR; Swamy BM; Herp A
Life Sci; 2001 Sep; 69(17):2039-50. PubMed ID: 11589519
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
16. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
18. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
19. [Effects of sirolimus on the growth of transplanted hepatocellular carcinoma].
Zhang J; Li H; Wang GS; Jiang N; Yang Y; Chen GH
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):413-6. PubMed ID: 19567017
[TBL] [Abstract][Full Text] [Related]
20. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
